pediatricjournalАрхив педиатрии и детской хирургииArchives of Pediatrics and Pediatric Surgery2949-46643033-6783НИКИ детства Минздрава Московской областиpediatricjournal-212Research ArticleОБЗОРЫREVIEWSЭВОЛЮЦИЯ УСТОЙЧИВОСТИ К ПЕНИЦИЛЛИНУ И МАКРОЛИДАМ У ВАКЦИННЫХ СЕРОТИПОВ Streptococcus pneumoniae (6B, 9V, 19F) В ЭПОХУ КОНЪЮГИРОВАННЫХ ВАКЦИНhttps://orcid.org/0009-0007-4383-8507ПавленкоЕкатерина Валерьевнаpavlenkoev5@gmail.comhttps://orcid.org/0000-0001-5540-924XБочароваКсения АлександровнаBocharova_k@bsuedu.ruhttps://orcid.org/0009-0002-5834-9320БурцевАндрей Руслановичandreyburtsev31@gmail.comБелгородский государственный национально-исследовательский университет, Россия, 308015, г. Белгород, ул. Победы, 85,20260506202641212Copyright © Павленко Е.В., Бочарова К.А., Бурцев А.Р., 20262026Павленко Е.В., Бочарова К.А., Бурцев А.Р.Павленко Е.В., Бочарова К.А., Бурцев А.Р.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nikid.ru/jour/article/view/212

Антибиотикорезистентность Streptococcus pneumoniae остаётся одной из ключевых проблем современной клинической микробиологии и инфекционной терапии. Серотипы 6B, 9V и 19F традиционно ассоциируются с повышенной устойчивостью к бета-лактамам и макролидам, формированием множественной лекарственной устойчивости (МЛУ) и высокой эпидемиологической значимостью. В обзоре систематически проанализированы молекулярно-генетические механизмы резистентности, эволюция устойчивости в эпоху внедрения конъюгированных пневмококковых вакцин (PCV7, PCV10, PCV13), региональные особенности распространения данных серотипов и их клиническое значение. Особое внимание уделено феномену серотип-замещения, роли клональных комплексов ST81, ST156, ST271 в распространении резистентности и перспективам разработки новых терапевтических стратегий. Представлены данные мета-анализов последних лет, демонстрирующие динамику изменения чувствительности к пенициллину и макролидам у целевых серотипов в различных географических регионах.

Streptococcus pneumoniaeсеротипы 6B9V19Fантибиотикорезистентностьпенициллинмакролидымножественная лекарственная устойчивостьсеротип-замещениеконъюгированные вакциныпенициллин-связывающие белкиReferencesObolski U. et al. The metabolic, virulence and antimicrobial resistance profiles of colonising Streptococcus pneumoniae shift after PCV13 introduction in urban Malawi // Nat. Commun. — 2023. — Vol. 14. — P. 7477. DOI: 10.1038/s41467-023-43160-yObolski U. et al. The metabolic, virulence and antimicrobial resistance profiles of colonising Streptococcus pneumoniae shift after PCV13 introduction in urban Malawi // Nat. Commun. — 2023. — Vol. 14. — P. 7477. DOI: 10.1038/s41467-023-43160-yHiller N.L., Orihuela C.J. Biological puzzles solved by using Streptococcus pneumoniae: a historical review of the pneumococcal studies that have impacted medicine and shaped molecular bacteriology // J. Bacteriol. — 2024. — Vol. 206. — P. e00059-24. DOI: 10.1128/jb.00059-24Hiller N.L., Orihuela C.J. Biological puzzles solved by using Streptococcus pneumoniae: a historical review of the pneumococcal studies that have impacted medicine and shaped molecular bacteriology // J. Bacteriol. — 2024. — Vol. 206. — P. e00059-24. DOI: 10.1128/jb.00059-24Subramanian K., Banerjee A. Deceiving the host: mechanisms of immune evasion and survival by pneumococcal bacteria // Front. Cell. Infect. Microbiol. — 2023. — Vol. 13. — P. 1231253. DOI: 10.3389/fcimb.2023.1231253Subramanian K., Banerjee A. Deceiving the host: mechanisms of immune evasion and survival by pneumococcal bacteria // Front. Cell. Infect. Microbiol. — 2023. — Vol. 13. — P. 1231253. DOI: 10.3389/fcimb.2023.1231253Chen C.H. et al. The microbiological characteristics and diagnosis of Streptococcus pneumoniae infection in the conjugate vaccine era // Hum. Vaccin. Immunother. — 2025. — Vol. 21, № 1. — P. 2497611. DOI: 10.1080/21645515.2025.2497611Chen C.H. et al. The microbiological characteristics and diagnosis of Streptococcus pneumoniae infection in the conjugate vaccine era // Hum. Vaccin. Immunother. — 2025. — Vol. 21, № 1. — P. 2497611. DOI: 10.1080/21645515.2025.2497611Savrasova L. et al. Streptococcus pneumoniae serotypes and factors associated with antimicrobial resistance in invasive pneumococcal disease cases in Latvia, 2012–2022 // Front. Public Health. — 2025. — Vol. 13. — P. 1501821. DOI: 10.3389/fpubh.2025.1501821Savrasova L. et al. Streptococcus pneumoniae serotypes and factors associated with antimicrobial resistance in invasive pneumococcal disease cases in Latvia, 2012–2022 // Front. Public Health. — 2025. — Vol. 13. — P. 1501821. DOI: 10.3389/fpubh.2025.1501821Feemster K. et al. Implications of Cross-Reactivity and Cross-Protection for Pneumococcal Vaccine Development // Vaccines. — 2024. — Vol. 12, № 9. — P. 974. DOI: 10.3390/vaccines13080831Feemster K. et al. Implications of Cross-Reactivity and Cross-Protection for Pneumococcal Vaccine Development // Vaccines. — 2024. — Vol. 12, № 9. — P. 974. DOI: 10.3390/vaccines13080831Lin T.Y. et al. Pneumococcal serotype prevalence and antibiotic resistance in children in South and Southeast Asia, 2012–2024 // Hum. Vaccin. Immunother. — 2024. — Vol. 20, № 1. — P. 2417554. DOI: 10.1080/21645515.2024.2417554Lin T.Y. et al. Pneumococcal serotype prevalence and antibiotic resistance in children in South and Southeast Asia, 2012–2024 // Hum. Vaccin. Immunother. — 2024. — Vol. 20, № 1. — P. 2417554. DOI: 10.1080/21645515.2024.2417554De Miguel S. et al. Distribution of Multidrug-Resistant Invasive Serotypes of Streptococcus pneumoniae during the Period 2007–2021 in Madrid, Spain // Antibiotics. — 2023. — Vol. 12, № 2. — P. 342. DOI: 10.3390/antibiotics12020342De Miguel S. et al. Distribution of Multidrug-Resistant Invasive Serotypes of Streptococcus pneumoniae during the Period 2007–2021 in Madrid, Spain // Antibiotics. — 2023. — Vol. 12, № 2. — P. 342. DOI: 10.3390/antibiotics12020342Lei Z. et al. In-vitro antimicrobial activity of new antimicrobial agents against Streptococcus pneumoniae and potential resistance mechanisms: a multicenter study // BMC Microbiol. — 2025. — Vol. 25. — P. 255. DOI: 10.1186/s12866-025-03967-9Lei Z. et al. In-vitro antimicrobial activity of new antimicrobial agents against Streptococcus pneumoniae and potential resistance mechanisms: a multicenter study // BMC Microbiol. — 2025. — Vol. 25. — P. 255. DOI: 10.1186/s12866-025-03967-9Song J. et al. Population structure, antibiotic resistance and molecular characteristics of Streptococcus pneumoniae causing invasive disease in Hubei, China // J. Med. Microbiol. — 2025. — Vol. 74, № 5. — P. 002015. DOI: 10.1099/jmm.0.002015Song J. et al. Population structure, antibiotic resistance and molecular characteristics of Streptococcus pneumoniae causing invasive disease in Hubei, China // J. Med. Microbiol. — 2025. — Vol. 74, № 5. — P. 002015. DOI: 10.1099/jmm.0.002015Rajput P. et al. Evaluation of Antibiotic Resistance Mechanisms in Gram-Positive Bacteria // Antibiotics. — 2024. — Vol. 13, № 12. — P. 1197. DOI: 10.3390/antibiotics13121197Rajput P. et al. Evaluation of Antibiotic Resistance Mechanisms in Gram-Positive Bacteria // Antibiotics. — 2024. — Vol. 13, № 12. — P. 1197. DOI: 10.3390/antibiotics13121197Kadioglu A., Weiser J.N., Paton J.C., Andrew P.W. The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease // Nat. Rev. Microbiol. — 2008. — Vol. 6, № 4. — P. 288–301. DOI: 10.1038/nrmicro1871Kadioglu A., Weiser J.N., Paton J.C., Andrew P.W. The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease // Nat. Rev. Microbiol. — 2008. — Vol. 6, № 4. — P. 288–301. DOI: 10.1038/nrmicro1871Mitchell T.J. The pathogenesis of streptococcal infections: from tooth decay to meningitis // Nat. Rev. Microbiol. — 2003. — Vol. 1, № 3. — P. 219–230. DOI: 10.1038/nrmicro771Mitchell T.J. The pathogenesis of streptococcal infections: from tooth decay to meningitis // Nat. Rev. Microbiol. — 2003. — Vol. 1, № 3. — P. 219–230. DOI: 10.1038/nrmicro771López R., García E. Recent trends on the molecular biology of pneumococcal capsules, lytic enzymes, and bacteriophage // FEMS Microbiol. Rev. — 2004. — Vol. 28, № 5. — P. 553–580. DOI: 10.1016/j.femsre.2004.05.006López R., García E. Recent trends on the molecular biology of pneumococcal capsules, lytic enzymes, and bacteriophage // FEMS Microbiol. Rev. — 2004. — Vol. 28, № 5. — P. 553–580. DOI: 10.1016/j.femsre.2004.05.006Hammerschmidt S. Adherence molecules of pathogenic pneumococci // Curr. Opin. Microbiol. — 2006. — Vol. 9, № 1. — P. 12–20. DOI: 10.1016/j.mib.2005.11.001Hammerschmidt S. Adherence molecules of pathogenic pneumococci // Curr. Opin. Microbiol. — 2006. — Vol. 9, № 1. — P. 12–20. DOI: 10.1016/j.mib.2005.11.001Bogaert D., De Groot R., Hermans P.W.M. Streptococcus pneumoniae colonisation: the key to pneumococcal disease // Lancet Infect. Dis. — 2004. — Vol. 4, № 3. — P. 144–154. DOI: 10.1016/S1473-3099(04)00938-7Bogaert D., De Groot R., Hermans P.W.M. Streptococcus pneumoniae colonisation: the key to pneumococcal disease // Lancet Infect. Dis. — 2004. — Vol. 4, № 3. — P. 144–154. DOI: 10.1016/S1473-3099(04)00938-7Lund E., Henrichsen J. Laboratory diagnosis, serology and epidemiology of Streptococcus pneumoniae // Methods Microbiol. — 1978. — Vol. 12. — P. 241–262. DOI: 10.1016/S0580-9517(08)70600-3Lund E., Henrichsen J. Laboratory diagnosis, serology and epidemiology of Streptococcus pneumoniae // Methods Microbiol. — 1978. — Vol. 12. — P. 241–262. DOI: 10.1016/S0580-9517(08)70600-3Pai R., Gertz R.E., Beall B. Sequential multiplex PCR approach for determining capsular serotypes of Streptococcus pneumoniae isolates // J. Clin. Microbiol. — 2006. — Vol. 44, № 1. — P. 124–131. DOI: 10.1128/JCM.44.1.124-131.2006Pai R., Gertz R.E., Beall B. Sequential multiplex PCR approach for determining capsular serotypes of Streptococcus pneumoniae isolates // J. Clin. Microbiol. — 2006. — Vol. 44, № 1. — P. 124–131. DOI: 10.1128/JCM.44.1.124-131.2006Park I.H. et al. Genetic, biochemical, and serological characterization of a new pneumococcal serotype, 6H, and generation of a pneumococcal strain producing three different capsular repeat units // Clin. Vaccine Immunol. — 2015. — Vol. 22, № 3. — P. 313–318. DOI: 10.1128/CVI.00732-14Park I.H. et al. Genetic, biochemical, and serological characterization of a new pneumococcal serotype, 6H, and generation of a pneumococcal strain producing three different capsular repeat units // Clin. Vaccine Immunol. — 2015. — Vol. 22, № 3. — P. 313–318. DOI: 10.1128/CVI.00732-14Hausdorff W.P., Bryant J., Paradiso P.R., Siber G.R. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I // Clin. Infect. Dis. — 2000. — Vol. 30, № 1. — P. 100–121. DOI: 10.1086/313608Hausdorff W.P., Bryant J., Paradiso P.R., Siber G.R. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I // Clin. Infect. Dis. — 2000. — Vol. 30, № 1. — P. 100–121. DOI: 10.1086/313608Black S. et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children // Pediatr. Infect. Dis. J. — 2000. — Vol. 19, № 3. — P. 187–195. DOI: 10.1097/00006454-200003000-00003Black S. et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children // Pediatr. Infect. Dis. J. — 2000. — Vol. 19, № 3. — P. 187–195. DOI: 10.1097/00006454-200003000-00003Palmu A.A. et al. Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Finland: a nationwide, population-based, cluster-randomised trial // Lancet. — 2012. — Vol. 380, № 9846. — P. 1191–1202. DOI: 10.1016/S0140-6736(12)61250-4Palmu A.A. et al. Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Finland: a nationwide, population-based, cluster-randomised trial // Lancet. — 2012. — Vol. 380, № 9846. — P. 1191–1202. DOI: 10.1016/S0140-6736(12)61250-4Pollard A.J. et al. Specific T cell frequencies and cytokine profiles are associated with protection against invasive pneumococcal disease // J. Infect. Dis. — 2023. — Vol. 228, № 4. — P. 412–421. DOI: 10.1093/infdis/jiad146Pollard A.J. et al. Specific T cell frequencies and cytokine profiles are associated with protection against invasive pneumococcal disease // J. Infect. Dis. — 2023. — Vol. 228, № 4. — P. 412–421. DOI: 10.1093/infdis/jiad146Whitney C.G. et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine // N. Engl. J. Med. — 2003. — Vol. 348, № 18. — P. 1737–1746. DOI: 10.1056/NEJMoa022823Whitney C.G. et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine // N. Engl. J. Med. — 2003. — Vol. 348, № 18. — P. 1737–1746. DOI: 10.1056/NEJMoa022823Weinberger D.M., Malley R., Lipsitch M. Serotype replacement in disease after pneumococcal vaccination // Lancet. — 2011. — Vol. 378, № 9807. — P. 1962–1973. DOI: 10.1016/S0140-6736(10)62225-8Weinberger D.M., Malley R., Lipsitch M. Serotype replacement in disease after pneumococcal vaccination // Lancet. — 2011. — Vol. 378, № 9807. — P. 1962–1973. DOI: 10.1016/S0140-6736(10)62225-8Zapun A., Contreras-Martel C., Vernet T. Penicillin-binding proteins and beta-lactam resistance // FEMS Microbiol. Rev. — 2008. — Vol. 32, № 2. — P. 361–385. DOI: 10.1111/j.1574-6976.2007.00095.xZapun A., Contreras-Martel C., Vernet T. Penicillin-binding proteins and beta-lactam resistance // FEMS Microbiol. Rev. — 2008. — Vol. 32, № 2. — P. 361–385. DOI: 10.1111/j.1574-6976.2007.00095.xHakenbeck R., Brückner R., Denapaite D., Maurer P. Molecular mechanisms of beta-lactam resistance in Streptococcus pneumoniae // Future Microbiol. — 2012. — Vol. 7, № 3. — P. 395–410. DOI: 10.2217/fmb.12.2Hakenbeck R., Brückner R., Denapaite D., Maurer P. Molecular mechanisms of beta-lactam resistance in Streptococcus pneumoniae // Future Microbiol. — 2012. — Vol. 7, № 3. — P. 395–410. DOI: 10.2217/fmb.12.2Smith A.M., Klugman K.P. Alterations in PBP 1A essential for high-level penicillin resistance in Streptococcus pneumoniae // Antimicrob. Agents Chemother. — 1998. — Vol. 42, № 6. — P. 1329–1333. DOI: 10.1128/AAC.42.6.1329Smith A.M., Klugman K.P. Alterations in PBP 1A essential for high-level penicillin resistance in Streptococcus pneumoniae // Antimicrob. Agents Chemother. — 1998. — Vol. 42, № 6. — P. 1329–1333. DOI: 10.1128/AAC.42.6.1329Coffey T.J. et al. Recombinational exchanges at the capsular polysaccharide biosynthetic locus lead to frequent serotype changes among natural isolates of Streptococcus pneumoniae // Mol. Microbiol. — 1991. — Vol. 5, № 9. — P. 2259–2269. DOI: 10.1111/j.1365-2958.1991.tb02121.xCoffey T.J. et al. Recombinational exchanges at the capsular polysaccharide biosynthetic locus lead to frequent serotype changes among natural isolates of Streptococcus pneumoniae // Mol. Microbiol. — 1991. — Vol. 5, № 9. — P. 2259–2269. DOI: 10.1111/j.1365-2958.1991.tb02121.xGrebe T., Hakenbeck R. Penicillin-binding proteins 2b and 2x of Streptococcus pneumoniae are primary resistance determinants for different classes of beta-lactam antibiotics // Antimicrob. Agents Chemother. — 1996. — Vol. 40, № 4. — P. 829–834. DOI: 10.1128/AAC.40.4.829Grebe T., Hakenbeck R. Penicillin-binding proteins 2b and 2x of Streptococcus pneumoniae are primary resistance determinants for different classes of beta-lactam antibiotics // Antimicrob. Agents Chemother. — 1996. — Vol. 40, № 4. — P. 829–834. DOI: 10.1128/AAC.40.4.829Dowson C.G., Hutchison A., Brannigan J.A. et al. Horizontal transfer of penicillin-binding protein genes in penicillin-resistant clinical isolates of Streptococcus pneumoniae // Proc. Natl. Acad. Sci. USA. — 1989. — Vol. 86, № 22. — P. 8842–8846. DOI: 10.1073/pnas.86.22.8842Dowson C.G., Hutchison A., Brannigan J.A. et al. Horizontal transfer of penicillin-binding protein genes in penicillin-resistant clinical isolates of Streptococcus pneumoniae // Proc. Natl. Acad. Sci. USA. — 1989. — Vol. 86, № 22. — P. 8842–8846. DOI: 10.1073/pnas.86.22.8842Laible G., Hakenbeck R. Five independent combinations of mutations can result in low-affinity penicillin-binding protein 2x of Streptococcus pneumoniae // J. Bacteriol. — 1991. — Vol. 173, № 20. — P. 6986–6990. DOI: 10.1128/jb.173.20.6986-6990.1991Laible G., Hakenbeck R. Five independent combinations of mutations can result in low-affinity penicillin-binding protein 2x of Streptococcus pneumoniae // J. Bacteriol. — 1991. — Vol. 173, № 20. — P. 6986–6990. DOI: 10.1128/jb.173.20.6986-6990.1991Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications // Clin. Infect. Dis. — 2002. — Vol. 34, № 4. — P. 482–492. DOI: 10.1086/324626Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications // Clin. Infect. Dis. — 2002. — Vol. 34, № 4. — P. 482–492. DOI: 10.1086/324626Sutcliffe J., Tait-Kamradt A., Wondrack L. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system // Antimicrob. Agents Chemother. — 1996. — Vol. 40, № 8. — P. 1817–1824. DOI: 10.1128/AAC.40.8.1817Sutcliffe J., Tait-Kamradt A., Wondrack L. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system // Antimicrob. Agents Chemother. — 1996. — Vol. 40, № 8. — P. 1817–1824. DOI: 10.1128/AAC.40.8.1817Tait-Kamradt A., Clancy J., Cronan M. et al. mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae // Antimicrob. Agents Chemother. — 1997. — Vol. 41, № 10. — P. 2251–2255. DOI: 10.1128/AAC.41.10.2251Tait-Kamradt A., Clancy J., Cronan M. et al. mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae // Antimicrob. Agents Chemother. — 1997. — Vol. 41, № 10. — P. 2251–2255. DOI: 10.1128/AAC.41.10.2251Canu A. et al. Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae // Antimicrob. Agents Chemother. — 2002. — Vol. 46, № 1. — P. 125–131. DOI: 10.1128/AAC.46.1.125-131.2002Canu A. et al. Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae // Antimicrob. Agents Chemother. — 2002. — Vol. 46, № 1. — P. 125–131. DOI: 10.1128/AAC.46.1.125-131.2002Magiorakos A.P. et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance // Clin. Microbiol. Infect. — 2012. — Vol. 18, № 3. — P. 268–281. DOI: 10.1111/j.1469-0691.2011.03570.xMagiorakos A.P. et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance // Clin. Microbiol. Infect. — 2012. — Vol. 18, № 3. — P. 268–281. DOI: 10.1111/j.1469-0691.2011.03570.xCroucher N.J. et al. Population genomics of post-vaccine changes in pneumococcal epidemiology // Nat. Genet. — 2013. — Vol. 45, № 6. — P. 656–663. DOI: 10.1038/ng.2625Croucher N.J. et al. Population genomics of post-vaccine changes in pneumococcal epidemiology // Nat. Genet. — 2013. — Vol. 45, № 6. — P. 656–663. DOI: 10.1038/ng.2625Robinson D.A. et al. Evolution and global dissemination of macrolide-resistant Streptococcus pneumoniae // J. Antimicrob. Chemother. — 2016. — Vol. 71, № 12. — P. 3337–3348. DOI: 10.1093/jac/dkw299Robinson D.A. et al. Evolution and global dissemination of macrolide-resistant Streptococcus pneumoniae // J. Antimicrob. Chemother. — 2016. — Vol. 71, № 12. — P. 3337–3348. DOI: 10.1093/jac/dkw299Butler J.C. et al. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's pneumococcal sentinel surveillance system // J. Infect. Dis. — 1996. — Vol. 174, № 5. — P. 986–993. DOI: 10.1093/infdis/174.5.986Butler J.C. et al. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's pneumococcal sentinel surveillance system // J. Infect. Dis. — 1996. — Vol. 174, № 5. — P. 986–993. DOI: 10.1093/infdis/174.5.986Brueggemann A.B. et al. Vaccine escape recombinants emerge after pneumococcal vaccination in the United States // PLoS Pathog. — 2007. — Vol. 3, № 11. — P. e168. DOI: 10.1371/journal.ppat.0030168Brueggemann A.B. et al. Vaccine escape recombinants emerge after pneumococcal vaccination in the United States // PLoS Pathog. — 2007. — Vol. 3, № 11. — P. e168. DOI: 10.1371/journal.ppat.0030168Lin T.Y. et al. Pneumococcal serotype prevalence and antibiotic resistance in children in South and Southeast Asia, 2012–2024 // Hum. Vaccin. Immunother. — 2024. — Vol. 20, № 1. — P. 2417554. DOI: 10.1080/21645515.2024.2417554Lin T.Y. et al. Pneumococcal serotype prevalence and antibiotic resistance in children in South and Southeast Asia, 2012–2024 // Hum. Vaccin. Immunother. — 2024. — Vol. 20, № 1. — P. 2417554. DOI: 10.1080/21645515.2024.2417554Althouse B.M. et al. Quantitative impact of children on pneumococcal carriage in the developing world // Clin. Infect. Dis. — 2013. — Vol. 57, № 10. — P. 1362–1369. DOI: 10.1093/cid/cit554Althouse B.M. et al. Quantitative impact of children on pneumococcal carriage in the developing world // Clin. Infect. Dis. — 2013. — Vol. 57, № 10. — P. 1362–1369. DOI: 10.1093/cid/cit554Enright M.C., Spratt B.G. The genomic contribution to antimicrobial resistance in Streptococcus pneumoniae // Curr. Opin. Microbiol. — 1999. — Vol. 2, № 5. — P. 561–565. DOI: 10.1016/S1369-5274(99)00021-8Enright M.C., Spratt B.G. The genomic contribution to antimicrobial resistance in Streptococcus pneumoniae // Curr. Opin. Microbiol. — 1999. — Vol. 2, № 5. — P. 561–565. DOI: 10.1016/S1369-5274(99)00021-8Coffey T.J. et al. Spread of an antibiotic-resistant pneumococcus: the role of serotype 6B // J. Infect. Dis. — 1995. — Vol. 171, № 1. — P. 222–226. DOI: 10.1093/infdis/171.1.222Coffey T.J. et al. Spread of an antibiotic-resistant pneumococcus: the role of serotype 6B // J. Infect. Dis. — 1995. — Vol. 171, № 1. — P. 222–226. DOI: 10.1093/infdis/171.1.222Song J.H. et al. Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study // Clin. Infect. Dis. — 2004. — Vol. 38, № 3. — P. 346–352. DOI: 10.1086/380637Song J.H. et al. Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study // Clin. Infect. Dis. — 2004. — Vol. 38, № 3. — P. 346–352. DOI: 10.1086/380637Weinberger D.M. et al. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis // Clin. Infect. Dis. — 2010. — Vol. 51, № 6. — P. 692–699. DOI: 10.1086/655828Weinberger D.M. et al. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis // Clin. Infect. Dis. — 2010. — Vol. 51, № 6. — P. 692–699. DOI: 10.1086/655828Nahm M.H. et al. Capsular switch in invasive pneumococci after introduction of heptavalent conjugate vaccine // PLoS One. — 2012. — Vol. 7, № 6. — P. e39059. DOI: 10.1371/journal.pone.0039059Nahm M.H. et al. Capsular switch in invasive pneumococci after introduction of heptavalent conjugate vaccine // PLoS One. — 2012. — Vol. 7, № 6. — P. e39059. DOI: 10.1371/journal.pone.0039059Fenoll A. et al. Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing systemic infections in Spain, 1979–1989 // Rev. Infect. Dis. — 1991. — Vol. 13, № 1. — P. 56–60. DOI: 10.1093/clinids/13.1.56Fenoll A. et al. Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing systemic infections in Spain, 1979–1989 // Rev. Infect. Dis. — 1991. — Vol. 13, № 1. — P. 56–60. DOI: 10.1093/clinids/13.1.56De Miguel S. et al. Distribution of Multidrug-Resistant Invasive Serotypes of Streptococcus pneumoniae during the Period 2007–2021 in Madrid, Spain // Antibiotics. — 2023. — Vol. 12, № 2. — P. 342. DOI: 10.3390/antibiotics12020342De Miguel S. et al. Distribution of Multidrug-Resistant Invasive Serotypes of Streptococcus pneumoniae during the Period 2007–2021 in Madrid, Spain // Antibiotics. — 2023. — Vol. 12, № 2. — P. 342. DOI: 10.3390/antibiotics12020342Ardanuy C. et al. Emergence of a multidrug-resistant clone (ST320) among invasive serotype 19A pneumococci in Spain // J. Antimicrob. Chemother. — 2009. — Vol. 64, № 3. — P. 507–510. DOI: 10.1093/jac/dkp221Ardanuy C. et al. Emergence of a multidrug-resistant clone (ST320) among invasive serotype 19A pneumococci in Spain // J. Antimicrob. Chemother. — 2009. — Vol. 64, № 3. — P. 507–510. DOI: 10.1093/jac/dkp221Klugman K.P. et al. Active Bacterial Core Surveillance of the Emerging Infections Program Network // Emerg. Infect. Dis. — 2001. — Vol. 7, № 1. — P. 92–99. DOI: 10.3201/eid0701.010115Klugman K.P. et al. Active Bacterial Core Surveillance of the Emerging Infections Program Network // Emerg. Infect. Dis. — 2001. — Vol. 7, № 1. — P. 92–99. DOI: 10.3201/eid0701.010115Doern G.V. et al. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study // Antimicrob. Agents Chemother. — 1997. — Vol. 41, № 2. — P. 292–297. DOI: 10.1128/AAC.41.2.292Doern G.V. et al. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study // Antimicrob. Agents Chemother. — 1997. — Vol. 41, № 2. — P. 292–297. DOI: 10.1128/AAC.41.2.292Syrogiannopoulos G.A. et al. Multicenter surveillance of Streptococcus pneumoniae in Greek hospitals: low prevalence of erythromycin resistance in young children // Clin. Microbiol. Infect. — 2001. — Vol. 7, № 9. — P. 513–521. DOI: 10.1046/j.1198-743x.2001.00347.xSyrogiannopoulos G.A. et al. Multicenter surveillance of Streptococcus pneumoniae in Greek hospitals: low prevalence of erythromycin resistance in young children // Clin. Microbiol. Infect. — 2001. — Vol. 7, № 9. — P. 513–521. DOI: 10.1046/j.1198-743x.2001.00347.xMcGee L. et al. Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network // J. Clin. Microbiol. — 2001. — Vol. 39, № 7. — P. 2565–2571. DOI: 10.1128/JCM.39.7.2565-2571.2001McGee L. et al. Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network // J. Clin. Microbiol. — 2001. — Vol. 39, № 7. — P. 2565–2571. DOI: 10.1128/JCM.39.7.2565-2571.2001Muñoz-Almagro C. et al. Molecular epidemiology of invasive Streptococcus pneumoniae in childhood in Barcelona // Pediatr. Infect. Dis. J. — 2008. — Vol. 27, № 8. — P. 722–727. DOI: 10.1097/INF.0b013e31816dbb6dMuñoz-Almagro C. et al. Molecular epidemiology of invasive Streptococcus pneumoniae in childhood in Barcelona // Pediatr. Infect. Dis. J. — 2008. — Vol. 27, № 8. — P. 722–727. DOI: 10.1097/INF.0b013e31816dbb6dHausdorff W.P. et al. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part II // Clin. Infect. Dis. — 2000. — Vol. 30, № 1. — P. 122–140. DOI: 10.1086/313603Hausdorff W.P. et al. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part II // Clin. Infect. Dis. — 2000. — Vol. 30, № 1. — P. 122–140. DOI: 10.1086/313603Dagan R. et al. Effect of a national campaign of 7-valent pneumococcal conjugate vaccine (PCV7) on invasive pneumococcal diseases (IPD) in Israeli children // Vaccine. — 2008. — Vol. 26, № 48. — P. 6117–6124. DOI: 10.1016/j.vaccine.2008.08.082Dagan R. et al. Effect of a national campaign of 7-valent pneumococcal conjugate vaccine (PCV7) on invasive pneumococcal diseases (IPD) in Israeli children // Vaccine. — 2008. — Vol. 26, № 48. — P. 6117–6124. DOI: 10.1016/j.vaccine.2008.08.082Ko K.S., Song J.H. Evolution of erythromycin-resistant Streptococcus pneumoniae from Asian countries that contains both erm(B) and mef(A) genes // J. Infect. Dis. — 2004. — Vol. 190, № 4. — P. 739–747. DOI: 10.1086/422625Ko K.S., Song J.H. Evolution of erythromycin-resistant Streptococcus pneumoniae from Asian countries that contains both erm(B) and mef(A) genes // J. Infect. Dis. — 2004. — Vol. 190, № 4. — P. 739–747. DOI: 10.1086/422625Lei Z. et al. In-vitro antimicrobial activity of new antimicrobial agents against Streptococcus pneumoniae and potential resistance mechanisms: a multicenter study // BMC Microbiol. — 2025. — Vol. 25. — P. 255. DOI: 10.1186/s12866-025-03967-9Lei Z. et al. In-vitro antimicrobial activity of new antimicrobial agents against Streptococcus pneumoniae and potential resistance mechanisms: a multicenter study // BMC Microbiol. — 2025. — Vol. 25. — P. 255. DOI: 10.1186/s12866-025-03967-9Ko K.S. et al. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA // Antimicrob. Agents Chemother. — 2003. — Vol. 47, № 8. — P. 2713–2715. DOI: 10.1128/AAC.47.8.2713-2715.2003Ko K.S. et al. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA // Antimicrob. Agents Chemother. — 2003. — Vol. 47, № 8. — P. 2713–2715. DOI: 10.1128/AAC.47.8.2713-2715.2003Song J.H. et al. Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study // Clin. Infect. Dis. — 2004. — Vol. 38, № 3. — P. 346–352. DOI: 10.1086/380637Song J.H. et al. Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study // Clin. Infect. Dis. — 2004. — Vol. 38, № 3. — P. 346–352. DOI: 10.1086/380637Ko K.S., Song J.H. Evolution of erythromycin-resistant Streptococcus pneumoniae from Asian countries that contains both erm(B) and mef(A) genes // J. Infect. Dis. — 2004. — Vol. 190, № 4. — P. 739–747. DOI: 10.1086/422625Ko K.S., Song J.H. Evolution of erythromycin-resistant Streptococcus pneumoniae from Asian countries that contains both erm(B) and mef(A) genes // J. Infect. Dis. — 2004. — Vol. 190, № 4. — P. 739–747. DOI: 10.1086/422625Melnyk A.H., Wong A., Kassen R. The fitness costs of antibiotic resistance mutations // Evol. Appl. — 2015. — Vol. 8, № 3. — P. 273–283. DOI: 10.1111/eva.12196Melnyk A.H., Wong A., Kassen R. The fitness costs of antibiotic resistance mutations // Evol. Appl. — 2015. — Vol. 8, № 3. — P. 273–283. DOI: 10.1111/eva.12196Weinberger D.M., Malley R., Lipsitch M. Serotype replacement in disease after pneumococcal vaccination // Lancet. — 2011. — Vol. 378, № 9807. — P. 1962–1973. DOI: 10.1016/S0140-6736(10)62225-8Weinberger D.M., Malley R., Lipsitch M. Serotype replacement in disease after pneumococcal vaccination // Lancet. — 2011. — Vol. 378, № 9807. — P. 1962–1973. DOI: 10.1016/S0140-6736(10)62225-8Lipsitch M. Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae // Emerg. Infect. Dis. — 2001. — Vol. 7, № 3. — P. 336–345. DOI: 10.3201/eid0703.010302Lipsitch M. Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae // Emerg. Infect. Dis. — 2001. — Vol. 7, № 3. — P. 336–345. DOI: 10.3201/eid0703.010302Croucher N.J. et al. Population genomics of post-vaccine changes in pneumococcal epidemiology // Nat. Genet. — 2013. — Vol. 45, № 6. — P. 656–663. DOI: 10.1038/ng.2625Croucher N.J. et al. Population genomics of post-vaccine changes in pneumococcal epidemiology // Nat. Genet. — 2013. — Vol. 45, № 6. — P. 656–663. DOI: 10.1038/ng.2625Golubchik T. et al. Pneumococcal genome sequencing tracks a vaccine escape variant formed through a multi-fragment recombination event // Nat. Genet. — 2012. — Vol. 44, № 3. — P. 352–355. DOI: 10.1038/ng.1072Golubchik T. et al. Pneumococcal genome sequencing tracks a vaccine escape variant formed through a multi-fragment recombination event // Nat. Genet. — 2012. — Vol. 44, № 3. — P. 352–355. DOI: 10.1038/ng.1072Moore M.R. et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005 // J. Infect. Dis. — 2008. — Vol. 197, № 7. — P. 1016–1027. DOI: 10.1086/528996Moore M.R. et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005 // J. Infect. Dis. — 2008. — Vol. 197, № 7. — P. 1016–1027. DOI: 10.1086/528996Pletz M.W. et al. Clonal spread of macrolide-resistant Streptococcus pneumoniae // J. Antimicrob. Chemother. — 2005. — Vol. 56, № 6. — P. 1023–1026. DOI: 10.1093/jac/dki394Pletz M.W. et al. Clonal spread of macrolide-resistant Streptococcus pneumoniae // J. Antimicrob. Chemother. — 2005. — Vol. 56, № 6. — P. 1023–1026. DOI: 10.1093/jac/dki394Park I.H. et al. Genetic, biochemical, and serological characterization of a new pneumococcal serotype, 6H // Clin. Vaccine Immunol. — 2015. — Vol. 22, № 3. — P. 313–318. DOI: 10.1128/CVI.00732-14Park I.H. et al. Genetic, biochemical, and serological characterization of a new pneumococcal serotype, 6H // Clin. Vaccine Immunol. — 2015. — Vol. 22, № 3. — P. 313–318. DOI: 10.1128/CVI.00732-14Hanquet G. et al. Impact of childhood pneumococcal vaccination on invasive pneumococcal disease in Europe: data from the SpIDnet surveillance network // Vaccine. — 2019. — Vol. 37, № 35. — P. 5180–5189. DOI: 10.1016/j.vaccine.2019.07.026Hanquet G. et al. Impact of childhood pneumococcal vaccination on invasive pneumococcal disease in Europe: data from the SpIDnet surveillance network // Vaccine. — 2019. — Vol. 37, № 35. — P. 5180–5189. DOI: 10.1016/j.vaccine.2019.07.026Fenoll A., Granizo J.J., Aguilar L., Giménez M.J. Comparison of the in vitro activity of several cephalosporins and penicillin against clinical isolates of Streptococcus pneumoniae // J. Antimicrob. Chemother. — 2000. — Vol. 46, № 5. — P. 763–766. DOI: 10.1093/jac/46.5.763Fenoll A., Granizo J.J., Aguilar L., Giménez M.J. Comparison of the in vitro activity of several cephalosporins and penicillin against clinical isolates of Streptococcus pneumoniae // J. Antimicrob. Chemother. — 2000. — Vol. 46, № 5. — P. 763–766. DOI: 10.1093/jac/46.5.763Moore M.R. et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance // Lancet Infect. Dis. — 2015. — Vol. 15, № 3. — P. 301–309. DOI: 10.1016/S1473-3099(14)71081-3Moore M.R. et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance // Lancet Infect. Dis. — 2015. — Vol. 15, № 3. — P. 301–309. DOI: 10.1016/S1473-3099(14)71081-3Tomczyk S. et al. Prevention of antibiotic-nonsusceptible invasive pneumococcal disease with the 13-valent pneumococcal conjugate vaccine // Clin. Infect. Dis. — 2016. — Vol. 62, № 9. — P. 1119–1125. DOI: 10.1093/cid/ciw085Tomczyk S. et al. Prevention of antibiotic-nonsusceptible invasive pneumococcal disease with the 13-valent pneumococcal conjugate vaccine // Clin. Infect. Dis. — 2016. — Vol. 62, № 9. — P. 1119–1125. DOI: 10.1093/cid/ciw085Laxminarayan R. et al. Antibiotic resistance—the need for global solutions // Lancet Infect. Dis. — 2013. — Vol. 13, № 12. — P. 1057–1098. DOI: 10.1016/S1473-3099(13)70318-9Laxminarayan R. et al. Antibiotic resistance—the need for global solutions // Lancet Infect. Dis. — 2013. — Vol. 13, № 12. — P. 1057–1098. DOI: 10.1016/S1473-3099(13)70318-9Song J.H. et al. Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study // Clin. Infect. Dis. — 2004. — Vol. 38, № 3. — P. 346–352. DOI: 10.1086/380637Song J.H. et al. Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study // Clin. Infect. Dis. — 2004. — Vol. 38, № 3. — P. 346–352. DOI: 10.1086/380637Sidorenko S.V., Reva I.D. Molecular epidemiology of Streptococcus pneumoniae in Russia // Klin. Lab. Diagn. — 2014. — № 5. — P. 9–14. (In Russ.)Sidorenko S.V., Reva I.D. Molecular epidemiology of Streptococcus pneumoniae in Russia // Klin. Lab. Diagn. — 2014. — № 5. — P. 9–14. (In Russ.)Kogan G. et al. Epidemiology and antibiotic resistance of Streptococcus pneumoniae in Russia: results of the multicenter surveillance study SPRINT // Antibiot. Khimioter. — 2017. — Vol. 62, № 9-10. — P. 24–32. (In Russ.)Kogan G. et al. Epidemiology and antibiotic resistance of Streptococcus pneumoniae in Russia: results of the multicenter surveillance study SPRINT // Antibiot. Khimioter. — 2017. — Vol. 62, № 9-10. — P. 24–32. (In Russ.)Klugman K.P. Pneumococcal resistance to antibiotics // Clin. Microbiol. Rev. — 1990. — Vol. 3, № 2. — P. 171–196. DOI: 10.1128/CMR.3.2.171Klugman K.P. Pneumococcal resistance to antibiotics // Clin. Microbiol. Rev. — 1990. — Vol. 3, № 2. — P. 171–196. DOI: 10.1128/CMR.3.2.171Mandell L.A. et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults // Clin. Infect. Dis. — 2007. — Vol. 44, Suppl. 2. — P. S27–S72. DOI: 10.1086/511159Mandell L.A. et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults // Clin. Infect. Dis. — 2007. — Vol. 44, Suppl. 2. — P. S27–S72. DOI: 10.1086/511159Smith K.J., Wateska A.R., Nowalk M.P., Zimmerman R.K. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine // JAMA. — 2012. — Vol. 307, № 8. — P. 804–812. DOI: 10.1001/jama.2012.169Smith K.J., Wateska A.R., Nowalk M.P., Zimmerman R.K. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine // JAMA. — 2012. — Vol. 307, № 8. — P. 804–812. DOI: 10.1001/jama.2012.169Yu V.L. et al. Association of Streptococcus pneumoniae antigenemia with poor prognosis in patients with community-acquired pneumonia // Clin. Infect. Dis. — 1996. — Vol. 22, № 3. — P. 449–450. DOI: 10.1093/clinids/22.3.449Yu V.L. et al. Association of Streptococcus pneumoniae antigenemia with poor prognosis in patients with community-acquired pneumonia // Clin. Infect. Dis. — 1996. — Vol. 22, № 3. — P. 449–450. DOI: 10.1093/clinids/22.3.449Dagan R., Klugman K.P. Impact of conjugate pneumococcal vaccines on antibiotic resistance // Lancet Infect. Dis. — 2008. — Vol. 8, № 12. — P. 785–795. DOI: 10.1016/S1473-3099(08)70281-0Dagan R., Klugman K.P. Impact of conjugate pneumococcal vaccines on antibiotic resistance // Lancet Infect. Dis. — 2008. — Vol. 8, № 12. — P. 785–795. DOI: 10.1016/S1473-3099(08)70281-0Pfizer Inc. FDA Approves PREVNAR 20™, Pfizer's Pneumococcal 20-valent Conjugate Vaccine for Adults // Press Release. — 2021. — June 8.Pfizer Inc. FDA Approves PREVNAR 20™, Pfizer's Pneumococcal 20-valent Conjugate Vaccine for Adults // Press Release. — 2021. — June 8.Pfaller M.A. et al. In vitro activity of delafloxacin against contemporary (2014) Gram-positive and -negative pathogens from the United States and Europe // Diagn. Microbiol. Infect. Dis. — 2016. — Vol. 86, № 4. — P. 383–389. DOI: 10.1016/j.diagmicrobio.2016.09.009Pfaller M.A. et al. In vitro activity of delafloxacin against contemporary (2014) Gram-positive and -negative pathogens from the United States and Europe // Diagn. Microbiol. Infect. Dis. — 2016. — Vol. 86, № 4. — P. 383–389. DOI: 10.1016/j.diagmicrobio.2016.09.009Livermore D.M. et al. In vitro activity of tedizolid against Gram-positive bacteria isolated from patients in the United States and Europe // Antimicrob. Agents Chemother. — 2015. — Vol. 59, № 9. — P. 5559–5565. DOI: 10.1128/AAC.00828-15Livermore D.M. et al. In vitro activity of tedizolid against Gram-positive bacteria isolated from patients in the United States and Europe // Antimicrob. Agents Chemother. — 2015. — Vol. 59, № 9. — P. 5559–5565. DOI: 10.1128/AAC.00828-15Loh B. et al. Novel antimicrobial peptides with potent activity against pneumococcal colonization and invasive disease // J. Infect. Dis. — 2023. — Vol. 228, № 3. — P. 289–301. DOI: 10.1093/infdis/jiad082Loh B. et al. Novel antimicrobial peptides with potent activity against pneumococcal colonization and invasive disease // J. Infect. Dis. — 2023. — Vol. 228, № 3. — P. 289–301. DOI: 10.1093/infdis/jiad082Fischetti V.A. Bacteriophage lysins as effective antibacterials // Curr. Opin. Microbiol. — 2008. — Vol. 11, № 5. — P. 393–400. DOI: 10.1016/j.mib.2008.09.012Fischetti V.A. Bacteriophage lysins as effective antibacterials // Curr. Opin. Microbiol. — 2008. — Vol. 11, № 5. — P. 393–400. DOI: 10.1016/j.mib.2008.09.012Burns T. et al. Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine (PCV20) in adults 60–64 years of age // Vaccine. — 2021. — Vol. 39, № 44. — P. 6519–6528. DOI: 10.1016/j.vaccine.2021.09.038Burns T. et al. Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine (PCV20) in adults 60–64 years of age // Vaccine. — 2021. — Vol. 39, № 44. — P. 6519–6528. DOI: 10.1016/j.vaccine.2021.09.038Tano K. et al. Can probiotics affect respiratory infections in children? // Acta Paediatr. — 2023. — Vol. 112, № 5. — P. 1023–1031. DOI: 10.1111/apa.16542Tano K. et al. Can probiotics affect respiratory infections in children? // Acta Paediatr. — 2023. — Vol. 112, № 5. — P. 1023–1031. DOI: 10.1111/apa.16542Croucher N.J. et al. Population genomics of post-vaccine changes in pneumococcal epidemiology // Nat. Genet. — 2013. — Vol. 45, № 6. — P. 656–663. DOI: 10.1038/ng.2625Croucher N.J. et al. Population genomics of post-vaccine changes in pneumococcal epidemiology // Nat. Genet. — 2013. — Vol. 45, № 6. — P. 656–663. DOI: 10.1038/ng.2625Giefing C. et al. Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies // J. Exp. Med. — 2008. — Vol. 205, № 1. — P. 117–131. DOI: 10.1084/jem.20071128Giefing C. et al. Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies // J. Exp. Med. — 2008. — Vol. 205, № 1. — P. 117–131. DOI: 10.1084/jem.20071128Melnyk A.H., Wong A., Kassen R. The fitness costs of antibiotic resistance mutations // Evol. Appl. — 2015. — Vol. 8, № 3. — P. 273–283. DOI: 10.1111/eva.12196Melnyk A.H., Wong A., Kassen R. The fitness costs of antibiotic resistance mutations // Evol. Appl. — 2015. — Vol. 8, № 3. — P. 273–283. DOI: 10.1111/eva.12196Lipsitch M., Siber G. How can vaccines contribute to solving the antimicrobial resistance problem? // mBio. — 2016. — Vol. 7, № 3. — P. e00428-16. DOI: 10.1128/mBio.00428-16Lipsitch M., Siber G. How can vaccines contribute to solving the antimicrobial resistance problem? // mBio. — 2016. — Vol. 7, № 3. — P. e00428-16. DOI: 10.1128/mBio.00428-16

The authors declare that there are no conflicts of interest present.